Lineage Cell Therapeutics, Inc.
LCTXLineage Cell Therapeutics, Inc. in brief
Lineage Cell Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Carlsbad, California, USA. It was founded in 1990. Its market value was $261 M on 30 October 2026, which makes it the 15,316th largest listed company in the world and the 2,986th largest in the USA on this site. In the year to December 2025 it had sales of $15 M and a net loss of $64 M. Brian M. Culley is its chief executive. Its largest product and service lines by sales in 2025 were Collaboration Revenues (93%), Event Based Milestones and Other Collaborative Revenue (49%) and Upfront license fees (44%). Its shares trade under the symbol LCTX (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a Clinical Stage Biotechnology company developing novel cellular therapies to treat unmet medical needs. The company total assets are 107.9 million USD as on 2020. The headquarters is in USA.
Lineage Cell Therapeutics, Inc. timeline
- 1990
- 🏁Founded
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- ✎Renamed Lineage Cell Therapeutics, Inc.Formerly Biotime Inc.
- 2022
- 💰Record revenue of $15 millionFY2022, the highest of the 8 years on record.
Events of Lineage Cell Therapeutics, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,476 (Jan 2022) · #3,869 (Dec 2022) · #3,587 (Jul 2023) · #3,201 (Jan 2024) · #1,323 (Mar 2026) · #2,933 (Aug 2026) · #3,051 (Oct 2026) · #2,990 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- 148.9×
- Price / sales (TTM)
- 24.0×
- Price / book
- 5.8×
- Free cash flow yield
- -7.5%
- Net margin (TTM)
- 16.1%
- Operating margin
- -251.5%
- Return on equity
- 3.9%
- Liabilities / assets
- 61.5%
- Revenue growth
- +53.3%
- R&D / revenue
- 121.8%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $15M | +53.3% | $-37M | $-64M | -436.3% |
| Dec 2024 | $10M | +6.3% | $-21M | $-19M | -195.9% |
| Dec 2023 | $9M | -39.2% | $-25M | $-21M | -240.4% |
| Dec 2022 | $15M | +238.7% | $-23M | $-26M | -178.7% |
| Dec 2021 | $4M | +137.2% | $-49M | $-43M | -991.2% |
| Dec 2020 | $2M | -48.0% | $-26M | $-21M | -1128.4% |
| Dec 2019 | $4M | -29.5% | $-39M | $-12M | -332.7% |
| Dec 2018 | $5M | — | $-42M | $-46M | -921.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-19M | $1M | $-19M | $-0.28 | — |
| Dec 2024 | $-23M | $1M | $-24M | $-0.09 | — |
| Dec 2023 | $-29M | $1M | $-29M | $-0.12 | — |
| Dec 2022 | $1M | $0M | $1M | $-0.15 | — |
| Dec 2021 | $-24M | $0M | $-24M | $-0.26 | — |
| Dec 2020 | $-20M | $0M | $-20M | $-0.14 | — |
| Dec 2019 | $-32M | $0M | $-32M | $-0.08 | — |
| Dec 2018 | $-31M | $1M | $-31M | $-0.36 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (-61.1% on a year earlier), net income $4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportMaterial agreement · Acquisition or disposal completed · Results of operations · Unregistered share sale · Regulation FD disclosure
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 12, 20268-KCurrent reportShareholder vote · Other events
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- Apr 29, 2026DEF 14AProxy statement
- Mar 11, 20268-KCurrent reportOther events
- Mar 5, 202610-KAnnual report · period to Dec 2025
- Mar 5, 20268-KCurrent reportResults of operations
- Nov 28, 20258-KCurrent reportOther events
Official filings of Lineage Cell Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $15 M
- Operating income
- $-37 M
- Net income
- $-64 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $113 M
- Total liabilities
- $69 M
- Total equity
- $45 M
As of December-2025
Top 100 institutional investors in Lineage Cell Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Broadwood Capital Inc | 49,560,992 | 0 (0.00%) | 19.59% | $47 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 13,870,871 | +683,976 (+5.19%) | 5.48% | $13 M | Nov 13, 2026 |
| 3 | Vanguard Capital Management LLC | 8,775,663 | -279,255 (-3.08%) | 3.47% | $8 M | Nov 13, 2026 |
| 4 | Defender Capital, LLC. | 6,648,899 | +50,000 (+0.76%) | 2.63% | $6 M | Oct 1, 2026 |
| 5 | Geode Capital Management, LLC | 5,339,354 | +39,897 (+0.75%) | 2.11% | $5 M | Nov 6, 2026 |
| 6 | Raffles Associates LP | 5,197,788 | 0 (0.00%) | 2.05% | $5 M | Nov 16, 2026 |
| 7 | Fifth Third Bancorp | 4,900,000 | +300,000 (+6.52%) | 1.94% | $5 M | Nov 5, 2026 |
| 8 | State Street Corp | 2,925,731 | +611,551 (+26.43%) | 1.16% | $3 M | Nov 12, 2026 |
| 9 | Millennium Management LLC | 2,628,150 | -390,417 (-12.93%) | 1.04% | $3 M | Nov 16, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 1,715,125 | +46,496 (+2.79%) | 0.68% | $2 M | Nov 13, 2026 |
| 11 | Northern Trust Corp | 1,657,655 | +1,004 (+0.06%) | 0.66% | $2 M | Nov 16, 2026 |
| 12 | Vanguard Portfolio Management LLC | 1,299,569 | +26,258 (+2.06%) | 0.51% | $1 M | Nov 13, 2026 |
| 13 | UBS Group AG | 1,160,527 | +473,476 (+68.91%) | 0.46% | $1 M | Nov 10, 2026 |
| 14 | Morgan Stanley | 810,539 | -660,923 (-44.92%) | 0.32% | $1 M | Nov 13, 2026 |
| 15 | Renaissance Technologies LLC | 674,529 | -670,300 (-49.84%) | 0.27% | $1 M | Nov 12, 2026 |
| 16 | Charles Schwab Investment Management Inc | 577,993 | +558 (+0.10%) | 0.23% | $1 M | Nov 16, 2026 |
| 17 | Goldman Sachs Group Inc | 537,965 | +104,699 (+24.17%) | 0.21% | $1 M | Nov 16, 2026 |
| 18 | Red Crane Wealth Management, LLC | 506,460 | -90,803 (-15.20%) | 0.20% | $0 M | Oct 14, 2026 |
| 19 | Hofer & Associates. Inc | 506,460 | New | 0.20% | $0 M | Oct 13, 2026 |
| 20 | Dauntless Investment Group, LLC | 422,500 | +422,400 (+422400.00%) | 0.17% | $0 M | Nov 16, 2026 |
| 21 | Barclays PLC | 394,628 | -114,040 (-22.42%) | 0.16% | $0 M | Nov 6, 2026 |
| 22 | Bank of New York Mellon Corp | 391,675 | 0 (0.00%) | 0.15% | $0 M | Nov 5, 2026 |
| 23 | Citadel Advisors LLC | 341,881 | -84,288 (-19.78%) | 0.14% | $0 M | Nov 16, 2026 |
| 24 | Flputnam Investment Management Co | 308,613 | +4,051 (+1.33%) | 0.12% | $0 M | Nov 13, 2026 |
| 25 | Quadrature Capital Ltd | 300,156 | +290,110 (+2887.82%) | 0.12% | $0 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Nuveen, LLC | 298,853 | +53,469 (+21.79%) | 0.12% | $0 M | Nov 10, 2026 |
| 27 | Connective Capital Management, LLC | 293,624 | New | 0.12% | $0 M | Nov 16, 2026 |
| 28 | BFC Planning, Inc. | 270,170 | 0 (0.00%) | 0.11% | $0 M | Nov 13, 2026 |
| 29 | Bridgeway Capital Management, LLC | 217,326 | -3,674 (-1.66%) | 0.09% | $0 M | Nov 16, 2026 |
| 30 | Empowered Funds, LLC | 217,326 | New | 0.09% | $0 M | Nov 13, 2026 |
| 31 | McMillan Office, Inc. | 216,000 | 0 (0.00%) | 0.09% | $0 M | Nov 13, 2026 |
| 32 | FMR LLC | 204,627 | +11,701 (+6.07%) | 0.08% | $0 M | Nov 10, 2026 |
| 33 | Marshall Wace, LLP | 203,391 | -1,078,956 (-84.14%) | 0.08% | $0 M | Nov 13, 2026 |
| 34 | Bank Of America Corp /de/ | 200,303 | -224,070 (-52.80%) | 0.08% | $0 M | Nov 16, 2026 |
| 35 | XTX Topco Ltd | 197,683 | +139,318 (+238.70%) | 0.08% | $0 M | Nov 16, 2026 |
| 36 | LPL Financial LLC | 191,122 | +164,484 (+617.48%) | 0.08% | $0 M | Nov 6, 2026 |
| 37 | Raymond James Financial Inc | 171,738 | +23,446 (+15.81%) | 0.07% | $0 M | Nov 12, 2026 |
| 38 | Stifel Financial Corp | 162,308 | New | 0.06% | $0 M | Nov 12, 2026 |
| 39 | Deutsche Bank AG\ | 160,783 | -22,541 (-12.30%) | 0.06% | $0 M | Nov 6, 2026 |
| 40 | Price T Rowe Associates Inc /MD/ | 151,233 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 41 | Two Sigma Investments, LP | 127,573 | +72,626 (+132.17%) | 0.05% | $0 M | Nov 16, 2026 |
| 42 | Rhumbline Advisers | 125,486 | -4,050 (-3.13%) | 0.05% | $0 M | Nov 10, 2026 |
| 43 | Susquehanna International Group, LLP | 108,582 | +46,155 (+73.93%) | 0.04% | $0 M | Nov 16, 2026 |
| 44 | HighTower Advisors, LLC | 104,870 | +5,000 (+5.01%) | 0.04% | $0 M | Nov 10, 2026 |
| 45 | Jpmorgan Chase & Co | 104,545 | +18,019 (+20.82%) | 0.04% | $0 M | Nov 12, 2026 |
| 46 | Williams Jones Wealth Management, LLC. | 101,300 | 0 (0.00%) | 0.04% | $0 M | Nov 5, 2026 |
| 47 | Invesco Ltd. | 99,001 | -1,128 (-1.13%) | 0.04% | $0 M | Nov 12, 2026 |
| 48 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 89,387 | +4,530 (+5.34%) | 0.04% | $0 M | Nov 16, 2026 |
| 49 | Vanguard Global Advisers, LLC | 86,682 | +887 (+1.03%) | 0.03% | $0 M | Nov 13, 2026 |
| 50 | Connecticut Wealth Management, LLC | 86,249 | New | 0.03% | $0 M | Oct 13, 2026 |
| 51 | Wealthspire Advisors, LLC | 80,088 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 52 | MetLife Investment Management, LLC | 79,604 | -30,697 (-27.83%) | 0.03% | $0 M | Nov 16, 2026 |
| 53 | Wells Fargo & Company/mn | 71,006 | -112,111 (-61.22%) | 0.03% | $0 M | Nov 16, 2026 |
| 54 | Police & Firemen's Retirement System of New Jersey | 54,351 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 55 | BNP Paribas Financial Markets | 49,976 | +12,073 (+31.85%) | 0.02% | $0 M | Nov 12, 2026 |
| 56 | CIBC World Market Inc. | 46,890 | -160 (-0.34%) | 0.02% | $0 M | Nov 10, 2026 |
| 57 | New York State Common Retirement Fund | 44,900 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 58 | Zacks Investment Management | 41,950 | -134 (-0.32%) | 0.02% | $0 M | Nov 16, 2026 |
| 59 | Larson Financial Group LLC | 40,933 | +40,783 (+27188.67%) | 0.02% | $0 M | Nov 5, 2026 |
| 60 | Voya Investment Management LLC | 37,232 | 0 (0.00%) | 0.01% | $0 M | Nov 10, 2026 |
| 61 | Rathbones Group PLC | 35,000 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 62 | Alliancebernstein L.P. | 34,020 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 63 | Equitable Holdings, Inc. | 30,012 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 64 | Prudential Financial Inc | 29,795 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 65 | StoneX Group Inc. | 29,747 | +12,739 (+74.90%) | 0.01% | $0 M | Nov 3, 2026 |
| 66 | Tableaux LLC | 29,300 | New | 0.01% | $0 M | Oct 23, 2026 |
| 67 | Point72 Asset Management, L.P. | 29,128 | New | 0.01% | $0 M | Nov 16, 2026 |
| 68 | Kestra Advisory Services, LLC | 27,847 | -10,000 (-26.42%) | 0.01% | $0 M | Nov 2, 2026 |
| 69 | Ascentis Independent Advisors | 25,245 | New | 0.01% | $0 M | Nov 3, 2026 |
| 70 | Beirne Wealth Consulting Services, LLC | 25,000 | -20,000 (-44.44%) | 0.01% | $0 M | Oct 19, 2026 |
| 71 | ProShare Advisors LLC | 23,138 | -991 (-4.11%) | 0.01% | $0 M | Oct 29, 2026 |
| 72 | Principal Financial Group Inc | 22,500 | +8,397 (+59.54%) | 0.01% | $0 M | Nov 2, 2026 |
| 73 | Royal Bank Of Canada | 22,376 | +16,385 (+273.49%) | 0.01% | $0 M | Nov 16, 2026 |
| 74 | CIBC Bancorp USA Inc. | 22,018 | +11,844 (+116.41%) | 0.01% | $0 M | Nov 13, 2026 |
| 75 | PFG Investments, LLC | 22,002 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 76 | Victory Capital Management Inc | 21,736 | +68 (+0.31%) | 0.01% | $0 M | Nov 10, 2026 |
| 77 | Chapin Davis, Inc. | 20,000 | -29 (-0.14%) | 0.01% | $0 M | Oct 9, 2026 |
| 78 | Allegheny Financial Group | 20,000 | 0 (0.00%) | 0.01% | $0 M | Nov 5, 2026 |
| 79 | Jane Street Group, LLC | 18,928 | -30,855 (-61.98%) | 0.01% | $0 M | Nov 12, 2026 |
| 80 | Legal & General Group Plc | 17,988 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 81 | Axxcess Wealth Management, LLC | 17,790 | New | 0.01% | $0 M | Oct 21, 2026 |
| 82 | Brevan Howard Capital Management LP | 17,466 | New | 0.01% | $0 M | Nov 16, 2026 |
| 83 | Citigroup Inc | 17,433 | -69,170 (-79.87%) | 0.01% | $0 M | Nov 4, 2026 |
| 84 | Xponance LLC | 17,219 | -303 (-1.73%) | 0.01% | $0 M | Nov 3, 2026 |
| 85 | Ameritas Investment Partners, Inc. | 16,724 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 86 | Two Sigma Securities, LLC | 16,107 | -21,686 (-57.38%) | 0.01% | $0 M | Nov 16, 2026 |
| 87 | Founders Capital Management | 16,000 | 0 (0.00%) | 0.01% | $0 M | Oct 13, 2026 |
| 88 | Private Advisor Group, LLC | 15,514 | New | 0.01% | $0 M | Nov 10, 2026 |
| 89 | First Trust Advisors LP | 15,346 | New | 0.01% | $0 M | Nov 12, 2026 |
| 90 | Anchyra Partners LLC | 15,141 | New | 0.01% | $0 M | Oct 13, 2026 |
| 91 | Russell Investments Group, Ltd. | 15,136 | +399 (+2.71%) | 0.01% | $0 M | Nov 6, 2026 |
| 92 | Mesirow Financial Investment Management, Inc. | 15,000 | -15,000 (-50.00%) | 0.01% | $0 M | Nov 5, 2026 |
| 93 | Elgethun Capital Management | 15,000 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 94 | ELCO Management Co., LLC | 15,000 | 0 (0.00%) | 0.01% | $0 M | Oct 14, 2026 |
| 95 | SkyOak Wealth, LLC | 15,000 | 0 (0.00%) | 0.01% | $0 M | Oct 28, 2026 |
| 96 | MAI Capital Management | 14,394 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 97 | Creative Planning | 13,770 | +170 (+1.25%) | 0.01% | $0 M | Nov 2, 2026 |
| 98 | Abel Hall, LLC | 13,090 | New | 0.01% | $0 M | Oct 19, 2026 |
| 99 | Manufacturers Life Insurance Company, The | 12,829 | New | 0.01% | $0 M | Nov 13, 2026 |
| 100 | Piscataqua Savings Bank | 12,499 | 0 (0.00%) | 0.00% | $0 M | Oct 21, 2026 |
Mutual funds holding Lineage Cell Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 5.91 M | $8 M | 2.3% | <0.01% | +6.4% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 4.16 M | $5 M | 1.6% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 2.96 M | $4 M | 1.2% | <0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 1.73 M | $2 M | 0.68% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.99 M | $2 M | 0.79% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 1.32 M | $2 M | 0.52% | 0.02% | −18% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 1.20 M | $2 M | 0.47% | <0.01% | −0.5% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 617,154 | $1 M | 0.24% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 438,359 | $1 M | 0.17% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 447,526 | $0 M | 0.18% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 346,304 | $0 M | 0.14% | <0.01% | +5.3% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 344,484 | $0 M | 0.14% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 221,000 | $0 M | 0.09% | 0.20% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 245,384 | $0 M | 0.10% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 193,554 | $0 M | 0.08% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 171,911 | $0 M | 0.07% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 136,900 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 107,870 | $0 M | 0.04% | <0.01% | +35% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 129,818 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 128,741 | $0 M | 0.05% | <0.01% | +8.4% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 95,428 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 93,589 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 92,474 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 94,219 | $0 M | 0.04% | <0.01% | +18% | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 88,027 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 62,541 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 51,620 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 51,282 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 41,359 | $0 M | 0.02% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 39,924 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 39,527 | $0 M | 0.02% | 0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 30,400 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 28,908 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 27,784 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 27,439 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 32,042 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 24,358 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 22,374 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 21,668 | $0 M | <0.01% | <0.01% | −20% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 21,580 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 16,722 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 16,724 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 16,642 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 14,858 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 14,737 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 15,991 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 14,103 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 11,340 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 11,340 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 6,357 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 5,660 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 4,652 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 4,391 | $0 M | <0.01% | <0.01% | +6.2% | Jun 30, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation | 4,300 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 54 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Lineage Cell Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Brian M. CulleyPresident and CEO, Director | Buy | +40,500 | $0.916 | $37 K | 296,016 | Form 4 |
| filed | Deborah J. AndrewsDirector | Buy | +25,000 | $0.800 | $20 K | 40,578 | Form 4 |
| filed | Jill Ann HoweChief Financial Officer | Buy | +20,000 | $0.855 | $17 K | 45,500 | Form 4 |
| filed | Brian M. CulleyPresident and CEO, Director | Buy | +15,000 | $1.630 | $24 K | 255,516 | Form 4 |
| filed | Brian M. CulleyPresident and CEO, Director | Option exercise | +31,250 | — | — | 253,385 | Form 4 |
| filed | George A. Samuel IIIGeneral Counsel and Secretary | Option exercise | +6,075 | — | — | 33,565 | Form 4 |
| filed | George A. Samuel IIIGeneral Counsel and Secretary | Shares withheld for tax | -2,502 | $1.800 | $5 K | 31,063 | Form 4 |
| filed | Brian M. CulleyPresident and CEO, Director | Shares withheld for tax | -12,869 | $1.800 | $23 K | 240,516 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Lineage Cell Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 4,298 shares at $1.03
- : 24,893 shares at $0.99
- : 26,826 shares at $0.91
- : 9,441 shares at $1.03
- : 5,939 shares at $0.90
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Lineage Cell Therapeutics, Inc. scorecard#
Passes 3 of the 20 checks that could be worked out: strongest in growth (2 of 6), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 5
- ✗P/E below its peers' median148.9×P/E 148.9× against Biotechnology's median of 17.5×.
- ✗Price to book below its peers' median5.8×Price to book 5.8× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median24.0×Price to sales 24.0× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-7.5%Free cash flow is -7.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yield0.7%Earnings yield 0.7% against the 10-year Treasury's 5.15% on 2026-11-13.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 6
- ✓Revenue grew in the newest year53.3%Revenue up 53.3% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-0.3%-0.3% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-0.3%-0.3% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.28 vs -0.09Diluted EPS -0.28 in fiscal 2025 against -0.09 the year before (report's currency).
- ✗Net income higher than five years earlier-$64 M-$64 M in fiscal 2025 against -$21 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$64 MNet income -$64 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-251.5%-251.5% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-103.4%-103.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-251.5%-251.5% in fiscal 2025 against -153.2% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.20 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-3.98Z-score -3.98 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year14.9%Diluted shares up 14.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Lineage Cell Therapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -251.5% | -60.5% | |
| Net margin | -436.3% | -68.9% | |
| Return on equity | -103.4% | -61.0% | |
| Revenue growth, 3 years a year | -0.3% | 12.9% | |
| Revenue growth | 53.3% | 15.8% | |
| Free cash flow margin | -133.5% | -61.5% |
3of 7on the Piotroski tests of financial strength
- Net loss of $64 million, the 9th loss-making year in a row.
- Free cash flow was negative: -$19 million.
- The share count rose 14.9% in the year.
Lineage Cell Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 15+53.2%100% | 9.5+6.2%100% | 8.9−39.2%100% | 15+239%100% | 4.3+138%100% | 1.8−48.1%100% | 3.5−29.5%100% | 5.0+44.2%100% | 3.5−41.6%100% | 5.9—100% | |
| Cost of revenue | — | 0.3−50.2%3.5% | 0.7−7.8%7.5% | 0.7−48.9%5.0% | 1.4+270%32.8% | 0.4−6.6%21.1% | 0.4+36.4%11.7% | 0.3+79.8%6.1% | 0.2−53.1%4.9% | 0.4—6.0% | |
| Gross profit | — | — | 8.3−40.8%92.5% | 14+379%95.0% | 2.9+102%67.2% | 1.4−53.6%78.9% | 3.1−33.8%88.3% | 4.7+42.4%93.9% | 3.3−40.9%95.1% | 5.6—94.0% | |
| Research and development | 18+42.2%122% | 12−20.6%131% | 16+12.3%176% | 14−58.8%95.1% | 34+175%781% | 12−31.4%675% | 18−14.3%511% | 21−12.8%420% | 24−33.5%695% | 36—610% | |
| General and administrative | 18+1.6%127% | 18+5.0%191% | 17−23.1%193% | 23+23.6%153% | 18+17.0%420% | 16−35.2%853% | 24−2.8%684% | 25+24.1%496% | 20−29.9%576% | 28—480% | |
| Operating expenses | — | — | 33−9.6%369% | 36−30.0%248% | 52+86.9%1201% | 28−33.6%1527% | 42−9.7%1194% | 46+5.8%932% | 44−31.9%1271% | 65—1090% | |
| Total costs and expenses | 51+65.2%352% | 31−8.0%326% | 34—377% | — | — | — | — | — | — | — | |
| Operating income | −37—−252% | −21—−226% | −25—−277% | −23—−153% | −49—−1134% | −26—−1448% | −39—−1106% | −42—−838% | −39—−1125% | −59—−996% | |
| Net interest income | — | — | — | 0.8+41350%5.6% | 0.0−99.8%0.0% | 1.0—56.9% | — | — | — | — | |
| Share of profit of associates | — | — | — | — | — | — | — | — | — | −4.7—−78.9% | |
| Other non-operating income (expense) | −32−1206%−220% | 2.9+99.6%30.5% | 1.5—16.2% | −3.3−155%−22.4% | 5.9+31.4%137% | 4.5−77.0%248% | 20—559% | −5.3−134%−107% | 16−79.9%452% | 78—1310% | |
| Income before tax | −69—−472% | −19—−196% | −23—−260% | −26—−176% | −43—−997% | −22—−1201% | −19—−547% | −47—−945% | −23−225%−673% | 19—314% | |
| Income tax | −5.3—−36.3% | 0—0.0% | −1.8−433%−20.2% | 0.5—3.7% | — | −1.2—−67.9% | −7.4r7.4−2241%−211% | 0.3r−0.3—6.9% | — | — | |
| Net income including minority interests | −63—−435% | −19—−196% | −21—−240% | −26—−179% | −43—−997% | −21—−1133% | −12—−336% | −47—−938% | −23−225%−673% | 19—314% | |
| Minority interests' share of net income | 0.2+515%1.1% | 0.0+286%0.3% | 0.0—0.1% | −0.1—−0.5% | −0.3—−5.8% | −0.0—−2.0% | −0.1—−3.4% | −0.8—−15.9% | −3.3—−95.8% | −15—−252% | |
| Net income attributable to shareholders | −64—−436% | −19—−196% | −21—−240% | −26—−179% | −43—−991% | −21—−1131% | −12—−333% | −46—−922% | −20−160%−578% | 34—567% | |
| Earnings per share, basic | -0.28—— | -0.09—— | -0.12—— | -0.15—— | -0.26—— | -0.14—— | -0.08—— | -0.36—— | -0.17−149%— | 0.35—— | |
| Earnings per share, diluted | -0.28—— | -0.09—— | -0.12—— | -0.15—— | -0.26—— | -0.14—— | -0.08—— | -0.36—— | -0.17−150%— | 0.34—— | |
| Shares, weighted average (basic) | 230+14.9%— | 200+15.9%— | 173+1.7%— | 170+3.2%— | 165—— | — | — | — | 114+17.6%— | 97—— | |
| Shares, weighted average (diluted) | 230+14.9%— | 200+15.9%— | 173+1.7%— | 170+103116%— | 0.2+9.6%— | 0.2+3.1%— | 0.1+14.7%— | 0.1r127−99.9%— | 114+15.0%— | 100—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 41−10.9%36.2% | 46+29.2%40.4% | 35+212%35.1% | 11−79.6%9.2% | 56+71.1%31.9% | 33+243%30.2% | 9.5−59.7%7.6% | 24−36.0%23.2% | 37+66.8%21.3% | 22r22—15.5% | |
| Short-term investments | 15+644%13.3% | 2.0+3932%1.8% | 0.1−99.9%0.0% | 47+1678%37.6% | 2.6−70.9%1.5% | 9.0−57.7%8.3% | 21+197%16.9% | 7.2+435%7.0% | 1.3—0.8% | — | |
| Receivables | 0.9+39.7%0.8% | 0.6−14.4%0.6% | 0.7+151%0.7% | 0.3−99.4%0.2% | 51—29.0% | — | 0.0−13.7%0.0% | 0.1−63.3%0.1% | 0.1−59.6%0.1% | 0.3—0.2% | |
| Other current assets | 2.5−2.7%2.2% | 2.6+15.9%2.3% | 2.2+20.6%2.2% | 1.8−22.2%1.5% | 2.4−3.4%1.3% | 2.4−15.0%2.3% | 2.9+50.8%2.3% | 1.9r1.9+35.4%1.9% | 1.4−21.1%0.8% | 1.8—1.2% | |
| Current assets | 59+16.0%52.5% | 51+32.7%45.0% | 38−35.9%38.1% | 60−46.2%48.5% | 112+154%63.9% | 44−23.5%40.8% | 58+58.2%45.8% | 36−14.7%35.8% | 43+66.2%24.6% | 26—18.0% | |
| Property, plant and equipment | 2.6+14.0%2.3% | 2.3+0.3%2.0% | 2.2r4.8−60.4%2.2% | 5.7+16.4%4.6% | 4.9−13.5%2.8% | 5.6−31.1%5.2% | 8.2+40.1%6.5% | 5.8+5.5%5.7% | 5.5+0.1%3.2% | 5.5—3.9% | |
| Right-of-use (leased) assets | 2.1−0.6%1.9% | 2.1−15.0%1.9% | 2.5—2.5% | — | — | 0.2−72.3%0.2% | 0.8—0.6% | — | — | — | |
| Goodwill | 110.0%9.5% | 110.0%9.4% | 110.0%10.6% | 110.0%8.6% | 110.0%6.1% | 110.0%9.9% | 11—8.5% | — | — | — | |
| Other intangible assets | 32−31.9%28.2% | 47−0.0%41.1% | 47−0.3%46.1% | 47−0.3%37.8% | 47−0.4%26.8% | 47−2.5%43.6% | 48+1444%38.5% | 3.1−54.7%3.1% | 6.9−32.4%4.0% | 10—7.2% | |
| Investments in associates | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Total assets | 113−0.6%100% | 113+12.1%100% | 101−18.3%100% | 124−29.2%100% | 175+61.7%100% | 108−14.0%100% | 125+23.4%100% | 102−41.3%100% | 173+21.5%100% | 143—100% | |
| Accounts payable | 2.3+99.4%2.1% | 1.2−42.7%1.0% | 2.1−14.3%2.0% | 2.4−32.5%1.9% | 3.5+35.7%2.0% | 2.6+7.6%2.4% | 2.4+2.9%1.9% | 2.4+151%2.3% | 0.9−41.1%0.5% | 1.6—1.1% | |
| Current liabilities | 11−18.7%10.1% | 14−22.2%12.3% | 18−5.4%17.8% | 19−59.7%15.3% | 47+506%27.0% | 7.8+19.6%7.2% | 6.5−4.7%5.2% | 6.8−1.0%6.7% | 6.9−22.3%4.0% | 8.9—6.2% | |
| Lease liabilities (non-current) | 1.5+18.5%1.4% | 1.3−34.6%1.1% | 2.0−30.8%2.0% | 2.9+47.3%2.3% | 1.9−22.8%1.1% | 2.5−35.0%2.3% | 3.9+109%3.1% | 1.9—1.8% | — | — | |
| Total liabilities | 69+91.2%61.5% | 36−7.2%32.0% | 39−24.6%38.6% | 52−38.2%41.8% | 84+552%47.9% | 13−9.9%11.9% | 14+51.2%11.3% | 9.4+4.9%9.3% | 9.0−25.6%5.2% | 12—8.5% | |
| Retained earnings | −467—−415% | −403—−356% | −385—−381% | −363—−294% | −337—−193% | −294—−272% | −273—−218% | −262—−258% | −216—−125% | −196—−138% | |
| Shareholders' equity | 45−43.2%39.6% | 78+23.6%69.2% | 63−13.5%62.8% | 73−20.5%59.3% | 92−4.1%52.8% | 96−14.8%89.1% | 113+22.5%90.0% | 92r94−43.3%90.7% | 163+37.9%93.9% | 118—82.7% | |
| Minority interests | −1.2—−1.1% | −1.4—−1.2% | −1.4—−1.4% | −1.4—−1.1% | −1.3—−0.8% | −1.1—−1.0% | −1.7—−1.4% | −1.6−198%−1.6% | 1.6−87.1%0.9% | 13—8.8% | |
| Total equity | 43−43.7%38.5% | 77+24.2%68.0% | 62−13.8%61.4% | 72−20.9%58.2% | 91−4.4%52.1% | 95−14.5%88.1% | 111+20.6%88.7% | 92−43.8%90.7% | 164+25.9%94.8% | 131—91.5% | |
| Total liabilities and equity | 113−0.6%100% | 113+12.1%100% | 101−18.3%100% | 124−29.2%100% | 175+61.7%100% | 108−14.0%100% | 125+23.4%100% | 102−41.3%100% | 173+21.5%100% | 143—100% | |
| Shares outstanding | 243+10.3%— | 220+26.0%— | 175+2.9%— | 170+0.4%— | 169+10.7%— | 153+2.2%— | 150r150+17.8%— | 127+0.2%— | 127+23.4%— | 103r103—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.7+19.1%4.8% | 0.6+4.4%6.2% | 0.6−3.4%6.3% | 0.6−12.2%4.0% | 0.7−19.4%15.3% | 0.8−17.9%45.1% | 1.0−7.3%28.5% | 1.1+14.1%21.7% | 0.9−19.7%27.4% | 1.2—19.9% | |
| Share-based compensation | 4.8−6.4%32.6% | 5.1+9.4%53.4% | 4.6+8.2%51.9% | 4.3+21.8%29.2% | 3.5+58.0%81.1% | 2.2−37.8%122% | 3.6−33.7%102% | 5.4+37.4%108% | 3.9−50.5%114% | 8.0—134% | |
| Cash from operating activities | −19—−130% | −23—−243% | −29−2797%−319% | 1.1—7.2% | −24—−543% | −20—−1082% | −32—−909% | −31—−619% | −31—−883% | −42—−715% | |
| Capital expenditure | −0.5—−3.6% | −0.6—−5.9% | −0.7—−7.5% | −0.4—−2.8% | −0.3r−0.4—−7.8% | −0.1—−3.5% | −0.4—−12.5% | −0.6—−11.1% | −1.3—−38.3% | −2.2—−38.0% | |
| Cash from investing activities | −13—−92.4% | −2.3−105%−24.3% | 46—519% | −46−574%−314% | 9.7−25.3%224% | 13−23.1%714% | 17+43.5%482% | 12—237% | −10—−296% | −11—−184% | |
| Debt repaid | — | — | — | — | — | — | −0.1—−2.0% | −0.1—−2.0% | −0.0—−1.4% | — | |
| Shares issued | — | — | 6.6+4376%74.1% | 0.1−99.5%1.0% | 31+502%711% | 5.1+4878%281% | 0.1—2.9% | — | 49+143%1413% | 20—340% | |
| Cash from financing activities | 27−24.8%185% | 36+458%377% | 6.4+294%71.8% | 1.6−95.6%11.1% | 37+23.7%851% | 30+4740%1636% | 0.6−89.3%17.6% | 5.8−89.6%116% | 55+69.0%1602% | 33—553% | |
| Exchange-rate effect on cash | 0.4—2.7% | −0.1—−1.0% | −0.3—−2.8% | −0.9—−5.9% | — | — | — | 0.0−94.1%0.1% | 0.1−65.4%2.9% | 0.3—4.9% | |
| Change in cash | −5.0−149%−34.6% | 10−56.9%109% | 24—269% | −44−292%−302% | 23+0.0%532% | 23—1264% | −14—−407% | −13−190%−266% | 15—427% | −20—−340% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 11+0.2%100% | 1.4−61.0%100% | 1.1−61.3%100% | 1.7+14.8%100% | 6.6*+130%100% | 3.7−2.6%100% | 2.8+96.4%100% | 1.5+4.0%100% | 2.9*+37.4%100% | 3.8—100% | 1.4—100% | 1.4—100% | 2.1—100% | |
| Cost of revenue | — | — | — | — | — | — | — | 0.0−63.3%2.4% | 0.2*−39.8%5.4% | 0.0—1.0% | 0.0—3.1% | 0.1—6.8% | 0.3*—12.3% | |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | 1.8*—87.7% | |
| Research and development | 21+63.1%194% | 3.8+16.7%266% | 4.8+53.7%447% | 4.2+36.0%245% | 8.2*+141%125% | 3.3+3.2%88.9% | 3.1+8.3%112% | 3.1+3.5%207% | 3.4*−12.4%119% | 3.2—83.9% | 2.9—204% | 3.0—208% | 3.9*—187% | |
| General and administrative | 20+11.5%185% | 4.9+17.5%343% | 5.2+14.4%488% | 5.1+4.7%295% | 4.9*+10.2%73.4% | 4.2−5.0%114% | 4.6+4.5%165% | 4.9−2.8%323% | 4.4*+2.6%153% | 4.4—117% | 4.4—310% | 5.0—346% | 4.3*—205% | |
| Operating expenses | — | — | — | — | — | — | — | — | — | — | — | — | 8.2—392% | |
| Total costs and expenses | 41−10.4%380% | 8.7+17.2%610% | 10.0−55.7%935% | 9.3+16.4%540% | 13*+64.9%199% | 7.5−2.0%203% | 23+210%815% | 8.0−1.2%533% | 8.0*−5.6%278% | 7.6—202% | 7.3—517% | 8.1—561% | 8.5*—405% | |
| Operating income | −30—−280% | −7.3—−510% | −8.9—−835% | −7.6—−440% | −6.5*—−99.1% | −3.8—−103% | −20—−715% | −6.5—−433% | −5.1*—−178% | −3.8—−102% | −5.9—−417% | −6.7—−461% | −6.4—−305% | |
| Other non-operating income (expense) | 27—253% | 12—839% | 10—979% | 2.8+18.7%163% | 2.2*+16.1%32.7% | −26−3195%−705% | −11−11360%−383% | 2.4+2193%157% | 1.9*+12.9%64.9% | 0.8—22.2% | 0.1—6.7% | 0.1—7.1% | 1.6*—78.9% | |
| Income before tax | — | 4.7—329% | — | — | −4.4*—−66.4% | −30—−808% | — | — | −3.3*—−113% | −3.0—−79.4% | −5.8—−410% | −6.6—−454% | −4.7*—−226% | |
| Income tax | — | 0.5—33.8% | — | — | −5.3*—−79.9% | 0—0.0% | — | — | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | |
| Net income including minority interests | 1.9—17.3% | 4.2—295% | 1.5—144% | −4.8—−278% | 0.9*—13.5% | −30—−808% | −30—−1098% | −4.1—−276% | −3.3*—−113% | −3.0—−79.4% | −5.8—−410% | −6.6—−454% | −4.7*—−226% | |
| Minority interests' share of net income | 0.1−16.2%1.1% | −0.0−107%−0.1% | 0.1−38.0%5.8% | 0.0—1.3% | 0.0*+78.3%0.6% | 0.0−12.1%0.8% | 0.1—3.6% | −0.0—−0.3% | 0.0*−62.3%0.8% | 0.0—0.9% | −0.0—−0.9% | −0.0—−1.1% | 0.1*—2.9% | |
| Net income attributable to shareholders | 1.8—16.2% | 4.2—295% | 1.5—139% | −4.8—−279% | 0.9*—12.9% | −30—−809% | −30—−1102% | −4.1—−276% | −3.3*—−114% | −3.0—−80.3% | −5.8—−409% | −6.5—−453% | −4.8—−229% | |
| Earnings per share, basic | — | 0.02—— | 0.01—— | -0.02—— | — | -0.13—— | -0.13—— | -0.02—— | — | -0.02—— | -0.03—— | -0.04—— | -0.03—— | |
| Earnings per share, diluted | — | -0.03—— | -0.03—— | -0.03—— | — | -0.13—— | -0.13—— | -0.02—— | — | -0.02—— | -0.03—— | -0.04—— | -0.03—— | |
| Shares, weighted average (basic) | 253+10.5%— | 253+10.5%— | 249+9.3%— | 245+8.4%— | — | 229+21.2%— | 228+20.9%— | 226+23.6%— | — | 189—— | 189—— | 183—— | — | |
| Shares, weighted average (diluted) | 259+13.2%— | 259+13.2%— | 261+14.5%— | 261+15.5%— | — | 229+21.2%— | 228+20.9%— | 226+23.6%— | — | 189—— | 189—— | 183—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 26—26.5% | 26−34.5%26.5% | 37−11.6%35.2% | 36−24.9%32.8% | 41−10.9%36.2% | 40+45.8%45.1% | 42+42.7%46.6% | 48+9.9%42.8% | 46+29.2%40.4% | 28—28.7% | 30—28.8% | 44—40.2% | 35—35.1% | |
| Short-term investments | 19—18.7% | 19+81104%18.7% | 13+79159%12.7% | 17+91700%15.9% | 15+644%13.3% | 0.0−99.5%0.0% | 0.0−99.8%0.0% | 0.0−57.8%0.0% | 2.0+3932%1.8% | 5.0—5.1% | 8.9—8.6% | 0.0—0.0% | 0.1—0.0% | |
| Receivables | 1.3—1.3% | 1.3+950%1.3% | 0.8+209%0.7% | 0.8+278%0.7% | 0.9+39.7%0.8% | 0.1−68.6%0.1% | 0.3+8.9%0.3% | 0.2+177%0.2% | 0.6−14.4%0.6% | 0.4—0.4% | 0.2—0.2% | 0.1—0.1% | 0.7—0.7% | |
| Other current assets | 1.3—1.3% | 1.3−23.2%1.3% | 1.4+3.9%1.3% | 2.0+5.9%1.8% | 2.5−2.7%2.2% | 1.6+28.2%1.8% | 1.3−21.6%1.4% | 1.9−7.5%1.7% | 2.6+15.9%2.3% | 1.3—1.3% | 1.7—1.6% | 2.0—1.9% | 2.2—2.2% | |
| Current assets | 48—47.7% | 48+13.0%47.7% | 53+20.8%49.9% | 56+12.4%51.3% | 59+16.0%52.5% | 42+22.8%47.1% | 44+8.6%48.3% | 50+9.3%44.7% | 51+32.7%45.0% | 34—35.6% | 40—39.3% | 46—42.1% | 38—38.1% | |
| Property, plant and equipment | 2.4—2.4% | 2.4+10.2%2.4% | 2.5+11.6%2.4% | 2.5+16.2%2.3% | 2.6+14.0%2.3% | 2.2+7.2%2.4% | 2.3+11.7%2.5% | 2.1+2.1%1.9% | 2.3+0.3%2.0% | 2.0—2.1% | 2.0—2.0% | 2.1—1.9% | 2.2r4.8—2.2% | |
| Right-of-use (leased) assets | 1.7—1.7% | 1.7−26.6%1.7% | 2.0+8.1%1.8% | 2.1+11.7%1.9% | 2.1−0.6%1.9% | 2.3−2.2%2.6% | 1.8−29.7%2.0% | 1.9−33.3%1.7% | 2.1−15.0%1.9% | 2.4—2.4% | 2.6—2.5% | 2.9—2.6% | 2.5—2.5% | |
| Goodwill | 11—10.7% | 110.0%10.7% | 110.0%10.0% | 110.0%9.7% | 110.0%9.5% | 110.0%11.9% | 110.0%11.8% | 110.0%9.5% | 110.0%9.4% | 11—11.0% | 11—10.4% | 11—9.8% | 11—10.6% | |
| Other intangible assets | 32—31.7% | 320.0%31.7% | 320.0%29.8% | 32−31.9%28.9% | 32−31.9%28.2% | 32−31.9%35.4% | 32−31.9%34.9% | 470.0%41.6% | 47−0.0%41.1% | 47—48.2% | 47—45.3% | 47—42.9% | 47—46.1% | |
| Total assets | 100—100% | 100+11.7%100% | 106+17.0%100% | 110−2.0%100% | 113−0.6%100% | 90−7.2%100% | 91−11.7%100% | 112+3.0%100% | 113+12.1%100% | 97—100% | 103—100% | 108—100% | 101—100% | |
| Accounts payable | 1.6—1.6% | 1.6+7.6%1.6% | 1.5+2.6%1.4% | 1.6−20.3%1.5% | 2.3+99.4%2.1% | 1.5−4.9%1.7% | 1.5−37.3%1.6% | 2.0−9.8%1.8% | 1.2−42.7%1.0% | 1.6—1.7% | 2.4—2.3% | 2.2—2.0% | 2.1—2.0% | |
| Current liabilities | 8.0—8.0% | 8.0−14.5%8.0% | 8.0−25.5%7.5% | 8.1−37.7%7.4% | 11−18.7%10.1% | 9.4−32.3%10.5% | 11−29.6%11.8% | 13−22.5%11.7% | 14−22.2%12.3% | 14—14.4% | 15—14.9% | 17—15.6% | 18—17.8% | |
| Lease liabilities (non-current) | 1.0—1.0% | 1.0−31.6%1.0% | 1.3+26.0%1.3% | 1.5+48.8%1.4% | 1.5+18.5%1.4% | 1.5−1.2%1.7% | 1.1−40.2%1.2% | 1.0−51.2%0.9% | 1.3−34.6%1.1% | 1.5—1.6% | 1.8—1.7% | 2.1—1.9% | 2.0—2.0% | |
| Total liabilities | 34—34.1% | 34−50.4%34.1% | 46+6.3%43.7% | 57+66.7%51.9% | 69+91.2%61.5% | 69+116%76.8% | 44+21.6%48.1% | 34−9.1%30.5% | 36−7.2%32.0% | 32—32.9% | 36—34.9% | 37—34.6% | 39—38.6% | |
| Retained earnings | −466—−466% | −466—−466% | −470—−443% | −472—−431% | −467—−415% | −468—−522% | −438—−482% | −408—−365% | −403—−356% | −400—−414% | −397—−386% | −391—−361% | −385—−381% | |
| Shareholders' equity | 67—67.0% | 67+204%67.0% | 61+25.9%57.3% | 54−31.8%49.2% | 45−43.2%39.6% | 22−66.7%24.6% | 48−29.2%53.3% | 79+9.2%70.7% | 78+23.6%69.2% | 66—68.5% | 68—66.4% | 72—66.7% | 63—62.8% | |
| Minority interests | −1.1—−1.1% | −1.1—−1.1% | −1.1—−1.1% | −1.2—−1.1% | −1.2—−1.1% | −1.2—−1.4% | −1.3—−1.4% | −1.4—−1.2% | −1.4—−1.2% | −1.4—−1.4% | −1.4—−1.4% | −1.4—−1.3% | −1.4—−1.4% | |
| Total equity | 66—65.9% | 66+217%65.9% | 60+26.9%56.3% | 53−32.1%48.1% | 43−43.7%38.5% | 21−67.9%23.2% | 47−29.6%51.9% | 78+9.4%69.5% | 77+24.2%68.0% | 65—67.1% | 67—65.1% | 71—65.4% | 62—61.4% | |
| Total liabilities and equity | 100—100% | 100+11.7%100% | 106+17.0%100% | 110−2.0%100% | 113−0.6%100% | 90−7.2%100% | 91−11.7%100% | 112+3.0%100% | 113+12.1%100% | 97—100% | 103—100% | 108—100% | 101—100% | |
| Shares outstanding | 253—— | 253+9.8%— | 253+10.8%— | 249+9.2%— | 243+10.3%— | 230+22.0%— | 228+20.9%— | 228+21.0%— | 220+26.0%— | 189—— | 189—— | 189—— | 175—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.8+14.9%7.0% | 0.2+13.5%14.1% | 0.2+9.4%17.5% | 0.2+14.6%10.9% | 0.2*+23.2%2.8% | 0.2+26.2%4.8% | 0.2+20.4%6.2% | 0.2+7.2%10.9% | 0.2*+5.6%5.3% | 0.1—3.7% | 0.1—10.1% | 0.2—10.6% | 0.1*—6.8% | |
| Share-based compensation | 5.6+12.2%51.4% | 1.7+42.0%119% | 1.6+29.3%150% | 1.2−3.7%67.9% | 1.1*−16.5%16.6% | 1.2−9.8%32.6% | 1.2−2.4%44.8% | 1.2+4.6%81.0% | 1.3*+24.1%45.9% | 1.3—35.2% | 1.3—90.1% | 1.2—80.5% | 1.1*—50.8% | |
| Cash from operating activities | −26—−238% | −5.6*—−392% | −7.2*—−678% | −8.1—−468% | −4.9*—−73.8% | −3.6*—−98.2% | −5.5*—−200% | −4.9—−325% | −6.3*—−221% | −5.8*—−153% | −5.2*—−368% | −5.8—−400% | −6.0*—−288% | |
| Capital expenditure | −0.6—−5.9% | −0.1*—−5.2% | −0.1*—−10.1% | −0.1—−3.2% | −0.4*—−6.0% | −0.0*—−0.3% | −0.0*—−0.5% | −0.1—−6.5% | −0.4*—−12.7% | −0.1*—−3.0% | −0.1*—−3.6% | −0.0—−2.6% | −0.1*—−4.4% | |
| Cash from investing activities | −19−518%−174% | −5.1*—−359% | 4.0*—370% | −2.3−222%−135% | −15*−682%−232% | −0.0*−100%−0.3% | −0.0*—−0.5% | 1.9—127% | 2.6*−73.0%91.9% | 3.9*—103% | −8.8*—−625% | −0.0—−2.6% | 9.7*—467% | |
| Shares issued | — | — | — | — | — | — | — | — | — | 0*—0.0% | 0.0*—2.3% | 14—972% | 0*—0.0% | |
| Cash from financing activities | 30+7.3%280% | −0.0*−101%−1.6% | 4.5*—418% | 5.6+10.2%322% | 20*−6.2%308% | 1.8*—49.8% | −0.3*−392%−11.1% | 5.0−64.0%336% | 22*—758% | −0.0*—−0.1% | 0.1*—7.5% | 14—971% | −0.0*—−0.6% | |
| Exchange-rate effect on cash | 0.4+46.5%3.3% | −0.1*—−5.6% | 0.3*−11.6%24.2% | −0.0—−0.3% | 0.2*+620%2.7% | −0.0*−111%−0.1% | 0.3*—10.6% | −0.1—−4.9% | 0.0*−91.1%0.9% | 0.0*—1.0% | −0.1*—−6.3% | −0.1—−4.8% | 0.3*—13.5% | |
| Change in cash | −14−210%−129% | −11*—−758% | 1.4*—135% | −4.8−344%−281% | 0.3*−98.1%5.3% | −1.8*—−48.8% | −5.6*—−201% | 2.0−75.5%132% | 18*+352%629% | −1.9*—−49.3% | −14*—−991% | 8.1—563% | 4.0*—191% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Lineage Cell Therapeutics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Collaboration Revenues$14 M93%+67%
- Event Based Milestones and Other Collaborative Revenue$7 M49%—
- Upfront license fees$6 M44%-21%
- Royalties, License and Other Revenues$1 M6.5%-30%
Countries and regions
- Non-US(total)$3 M17%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Lineage Cell Therapeutics, Inc. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | — |
| 🇮🇱 Israel | 1 subsidiary | — |
| 🇸🇬 Singapore | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Lineage Cell Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Brian Culley | $2.1 M | $6.3 M | $992 K | $95 |
| 2024Brian Culley | $2.5 M | $707 K | $1.1 M | $28 |
| 2023Brian Culley | $2.9 M | $2.2 M | $937 K | $62 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Lineage Cell Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Auditor changed 2 · Acquisition or sale completed 1 · Directors and officers 1 · Material agreement 2 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Acquisition or sale completedMaterial agreementUnregistered share saleResults announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2014 | $4 M | Private placement after listing | $2 to $10 million | 3 | equity, options | SEC |
| Mar 2011 | $4 M | Issued in a merger or acquisition | $2 to $10 million | 20 | equity, options | SEC |
| Jan 2011 | $2 M | Issued in a merger or acquisition | $2 to $10 million | 8 | equity | SEC |
| May 2010 | $8 M | No. 3 | $2 to $10 million | 2 | equity | SEC |
| May 2009 | $8 M | No. 2 | $2 to $10 million | 2 | equity, options | SEC |
| Apr 2009 | $4 M | No. 1 | $2 to $10 million | 29 | equity, debt | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Lineage Cell Therapeutics, Inc. compares in Biotechnology
- Market cap$261 M · higher than 49% of 726
- Revenue$15 M · higher than 47% of 647
- Net margin16.1% · higher than 82% of 408
- Revenue growth53.3% · higher than 73% of 438
- P/E ratio148.9× · lower than 6% of 100
- Price / sales24.0× · lower than 28% of 339
- Price / book5.8× · lower than 27% of 534
- FCF yield-7.5% · higher than 63% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Lineage Cell Therapeutics, Inc.🇺🇸 | $261 M | 148.9× | 16.1% | +53.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, Wikidata, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Lineage Cell Therapeutics, Inc.? Verify and update this profile — free
Show Lineage Cell Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.